Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers

ESMO 2021: Latest in EGFR mutated advanced NSCLC

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

ESMO 2021: PARPi data and their role in mono/combination therapies

ESMO 2021: Breast cancer roundup

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Welcome to APCCC 2021

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

ESMO 2021 Roundup